首页 / 院系成果 / 成果详情页

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study 期刊论文

编号：

7723a474-72cb-4d17-89db-5b2dd2425197
作者：

Li, Yuhong(李宇红)#^[1]Qiu, Miaozhen(邱妙珍)#^[1,2]Xu, Jianming(徐建明)#^[3]Sun, Guoping(孙国平)^[4]Lu, Huishan^[5];Liu, Yunpeng(刘云鹏)^[6]Zhong, Meizuo(钟美佐)^[7]Zhang, Helong(张贺龙)^[8]Yu, Shiying(于世英)^[9]Li, Wei(李薇)^[10]Hu, Xiaohua(胡晓桦)^[11]Wang, Jiejun(王杰军)^[12]Cheng, Ying(程颖)^[13]Zhou, Juntian^[14];Guo, Zengqing^[15];Guan, Zhongzhen(管忠震)^[1]Xu, Ruihua(徐瑞华)*^[1]
语种：

English
期刊：

ONCOTARGET ISSN：1949-2553 2015 年 6 卷 33 期 (35107 - 35115) ; OCT 27
Associated data：

ClinicalTrials.gov/NCT01198392
收录：
关键词：

gastric cancer first-line chemotherapy fluorouracil S-1
摘要：

The safety and efficacy of S-1 plus cisplatin in Chinese advanced gastric cancer patients in first line setting is unknown. In this pilot study, patients with advanced gastric or gastro-esophageal junction adenocarcinoma were enrolled and randomly assigned in a 1: 1 ratio to receive S-1 plus cisplatin (CS group) or 5-FU plus cisplatin (CF group). The primary endpoint was time to progression (TTP). Secondary end points included overall survival (OS) and safety. This study was registered on ClinicalTrials. Gov, number NCT01198392. A total of 236 patients were enrolled. Median TTP was 5.51 months in CS group compared with 4.62 months in CF group [hazard ratio (HR) 1.028, 95% confidential interval (CI) 0.758-1.394, p = 0.859]. Median OS was 10.00 months and 10.46 months in CS and CF groups (HR 1.046, 95% CI 0.709-1.543, p = 0.820), respectively. The most common adverse events in both groups were anemia, leukopenia, neutropenia, nausea, thrombocytopenia, vomiting, anorexia and diarrhea. We find that S-1 plus cisplatin is an effective and tolerable option for advanced gastric or gastro-esophageal junction adenocarcinoma patients in China.
推荐引用方式
GB/T 7714：

Li Yuhong,Qiu Miaozhen,Xu Jianming, et al. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study [J].ONCOTARGET,2015,6(33):35107-35115.
APA：

Li Yuhong,Qiu Miaozhen,Xu Jianming,Sun Guoping,&Xu Ruihua.(2015).S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study .ONCOTARGET,6(33):35107-35115.
MLA：

Li Yuhong, et al. "S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study" .ONCOTARGET 6,33(2015):35107-35115.
入库时间：

5/20/2019 5:36:39 PM
更新时间：

5/20/2019 5:36:39 PM
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：25  下载次数：0

分享到：

浏览次数：25

下载次数：0

打印次数：0